We believe that future studies will find the role of CALHM6 not limited to L. monocytogenes infection response or anti‐tumour DC therapy (Kasamatsu et al, 2014), but more broadly applicable to immune challenges in which the timing of the activation of immune cells and IFN‐γ production by NK cells are important for the correct downstream function of the immune response. The gene discussed is CALHM6; the disease is neoplasm.